A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy

Figures & data

Figure 1. Study flow-chart.

Table 1. Numbers and rates of adverse events reported by vaccination group and type of reaction.

	MMR+V (n=5,130)		MMRV (n=5,265)
	n	(%)	n	(%)	RR (95% CI)
Local reaction	490	(9.6)	151	(2.9)	3.33 (2.79–3.98)^*
pain	87	(1.7)	39	(0.7)	2.31 (1.58–3.38)^*
swelling	155	(3.0)	47	(0.9)	3.38 (2.45–4.68)^*
redness	296	(5.8)	62	(1.2)	4.89 (3.73–6.42)^*
blisters	64	(1.2)	17	(0.3)	3.90 (2.28–6.66)^*
Systemic reaction	2,567	(50.0)	2,736	(52.0)	0.96 (0.92–1.00)
fever ≤39.4°C	1,421	(27.7)	2,086	(39.6)	0.58 (0.54–0.63)^*
fever ≥39.5°C	199	(3.9)	245	(4.7)	0.80 (0.69–1.00)
irritability	655	(12.8)	497	(9.4)	1.35 (1.21–1.51)^*
skin blotches and marks	1,016	(19.8)	901	(17.1)	1.16 (1.07–1.26)^*
parotid swelling	37	(0.7)	22	(0.4)	1.73 (1.02–2.92)^*
arthralgia	55	(1.1)	31	(0.6)	1.82 (1.17–2.82)^*
febrile seizures	7	(0.14)	9	(0.17)	0.80 (0.30–2.15)
no febrile seizures	2	(0.04)	1	(0.02)	2.05 (0.18–22.6)
unrelated reaction	690	(13.5)	520	(9.9)	1.36 (1.22–1.52)^*
no reaction reported	1,869	(36.4)	2,009	(38.2)	0.95 (0.91–1.00)

* p < 0.05